Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Physiology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.
J Neuroimmunol. 2019 Mar 15;328:20-34. doi: 10.1016/j.jneuroim.2018.11.015. Epub 2018 Dec 1.
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) which predominantly affect young adults and undergo heavy socioeconomic burdens. Conventional therapeutic modalities for MS mostly downregulate aggressive immune responses and are almost insufficient for management of progressive course of the disease. Mesenchymal stem cells (MSCs), due to both immunomodulatory and neuroprotective properties have been known as practical cells for treatment of neurodegenerative diseases like MS. However, clinical translation of MSCs is associated with some limitations such as short-life engraftment duration, little in vivo trans-differentiation and restricted accessibility into damaged sites. Therefore, laboratory manipulation of MSCs can improve efficacy of MSCs transplantation in MS patients. In this review, we discuss several novel approaches, which can potentially enhance MSCs capabilities for treating MS.
多发性硬化症(MS)是一种中枢神经系统(CNS)的炎症性脱髓鞘疾病,主要影响年轻人,并带来沉重的社会经济负担。MS 的常规治疗方法主要下调侵袭性免疫反应,但对于疾病的进展过程几乎不够。间充质干细胞(MSCs)因其具有免疫调节和神经保护特性,已被认为是治疗多发性硬化症等神经退行性疾病的实用细胞。然而,MSCs 的临床转化存在一些局限性,例如植入持续时间短、体内转分化少以及进入损伤部位受限。因此,对 MSCs 的实验室操作可以提高 MSCs 移植治疗 MS 患者的疗效。在这篇综述中,我们讨论了几种可能增强 MSCs 治疗 MS 能力的新方法。